Today is #DNADay commemorating 70 years since “Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid” was published & 20 years since the completion of the Human Genome Project. Let’s take a historical look back...🧬 dnascience.plos.org/2023/04/20/sev…

Carl Kempe, hedersdoktor vid Umeå universitet och ständig sekreterare för Kempestiftelserna, har gått bort 84 år gammal. Hans engagemang har bidragit till att betydande finansiellt stöd givits till forskning och forskare på olika sätt. 🌹 Minnestext: umu.se/nyheter/carl-k…

Bench mate reunion at #GRCpancreas in Lucca Italy Daniel Öhlund

Happy to join the #SwedishCancerResearchMeeting 2023!

Jag är mycket hedrad över detta uppdrag 🙏🏻! Tack till Cancerfonden och min företrädare professor Klas Kärre! ”Standing on the shoulders of giants”

🔥NORPACT-1: Short-course neoadjuvant FOLFIRINOX vs surgery + adj. therapy for #PDAC #ASCO23 🔎12 Nordic centers, phs-2, 140 pts 👉52% completed neoadj. CTx 🤨mOS: 25.1 mo vs 38.5 mo ✅manageable safety, but no benefit of neoadj. FOLFIRINOX ESMO - Eur. Oncology OncoAlert

Congratulations to Joshua Cumming! PhD defence @UmeaUniversity yesterday. Great discussion with opponent Claus Jorgensen 🇪🇺🇩🇰.

I’m looking for a postdoc to the lab! umu.se/en/work-with-u…

Maréne Landström, Institutionen för medicinsk biovetenskap, har utsetts till Årets cancerforskare av Cancerfondens forskningsnämnd. Det är främst upptäckten av specialiserade antikroppar, som kan förhindra att prostatacancer sprider sig, som uppmärksammas. umu.se/nyheter/umeafo…

The results from the NORPACT-1 trial are out! Conclusion: no survival benefit from neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma compared with upfront surgery thelancet.com/journals/langa…

Our new review paper is out! Overcoming therapy resistance in pancreatic cancer: New insights and future directions doi.org/10.1016/j.bcp.…

Some highlights from the Botton-Champalimaud conference. Especially happy to see ⁦vincorbo⁩ and ⁦Daniel Öhlund⁩ continuing doing fab science. Nothing makes me happier than seeing good humans doing great. 💜💪🏻🌟

🔥🔥 new day, 🆕 #pancreas2000 project 📣🤩 Pooled OR for pancreatic steatosis (PS) in patients with PDAC vs. controls was 3.23 (95% CI 1.86-5.60). ⬇️ ⬇️ tinyurl.com/fatpanc We need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS.

🧵1/ Excited to share our latest review on how organoid technology is transforming pancreatic cancer research, published in Experimental & Molecular Medicine. Here's a breakdown of the key points. nature.com/articles/s1227…

Currently looking for a post-doc! umustipendie.varbi.com/en/what:job/jo…

Nature research paper: MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC go.nature.com/3XPqIz1

New paper published from our lab! Characterization of a new interferon-response CAFs with tumor-restraining properties. aacrjournals.org/cancerres/arti…

Currently looking for a post-doc! umustipendie.varbi.com/en/?jobtoken=1…

Back home from the Swedish Cancer Research Meeting in Malmö. Great meeting! Great contributions from our lab by Parniyan och Cedric!

Happy to share that our project on the role of galectins in immune evasion has been awarded 6 MSEK in funding from the ErlingPersson Foundation. Grateful to the entire lab team and to the foundation for their support!